| 1. |
|
|
| 2. |
|
|
| 3. |
|
|
| 4. |
- Mendez-Hernandez, H., et al.
(författare)
-
VALES VI: ISM enrichment in star-forming galaxies up to z similar to 0.2 using (CO)-C-12(1-0), (CO)-C-13(1-0), and (CO)-O-18(1-0) line luminosity ratios
- 2020
-
Ingår i: Monthly Notices of the Royal Astronomical Society. - : Oxford University Press (OUP). - 0035-8711 .- 1365-2966. ; 497:3, s. 2771-2785
-
Tidskriftsartikel (refereegranskat)abstract
- We present Atacama Large Millimeter/sub-millimeter Array (ALMA) observations towards 27 low-redshift (0.02< z< 0.2) starforming galaxies taken from the Valpara ' iso ALMA/APEX Line Emission Survey. We perform stacking analyses of the (CO)-C-12(1-0), (CO)-C-13(1-0), and (CO)-O-18(1-0) emission lines to explore the L' [(CO)-C-12(1-0)]/L' [(CO)-C-13(1-0)] [hereafter L' ((CO)-C-12)/L' ((CO)-C-13)] and L' [(CO)-C-13(1-0)]/L' [(CO)-O-18(1-0)] [hereafter L' ((CO)-C-13)/L' ((CO)-O-18)] line luminosity ratio dependence as a function of different global galaxy parameters related to the star formation activity. The sample has far-IR luminosities of 1010.1-11.9 L and stellar masses of 109.8-10.9M(circle dot) corresponding to typical star-forming and starburst galaxies at these redshifts. On average, we find an L' (12CO)/L' ((CO)-C-13) line luminosity ratio value of 16.1 +/- 2.5. Galaxies with pieces of evidence of possible merging activity tend to show higher L' ((CO)-C-12)/L' (13CO) ratios by a factor of 2, while variations of this order are also found in galaxy samples with higher star formation rates (SFRs) or star formation efficiencies (SFEs). We also find an average L' ((CO)-C-13)/L' ((CO)-O-18) line luminosity ratio of 2.5 +/- 0.6, which is in good agreement with those previously reported for starburst galaxies. We find that galaxy samples with high LIR, SFR, and SFE show low L' ((CO)-C-13)/L' ((CO)-O-18) line luminosity ratios with high L' ((CO)-C-12)/L' ((CO)-C-13) line luminosity ratios, suggesting that these trends are produced by selective enrichment of massive stars in young starbursts.
|
|
| 5. |
- Vermunt, L., et al.
(författare)
-
Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and APOE genotype
- 2019
-
Ingår i: Alzheimers & Dementia. - : Wiley. - 1552-5260 .- 1552-5279. ; 15:7, s. 888-898
-
Tidskriftsartikel (refereegranskat)abstract
- Introduction: We estimated the age-specific duration of the preclinical, prodromal, and dementia stages of Alzheimer's disease (AD) and the influence of sex, setting, apolipoprotein E (APOE) genotype, and cerebrospinal fluid tau on disease duration. Methods: We performed multistate modeling in a combined sample of 6 cohorts (n = 3268) with death as the end stage and estimated the preclinical, prodromal, and dementia stage duration. Results: The overall AD duration varied between 24 years (age 60) and 15 years (age 80). For individuals presenting with preclinical AD, age 70, the estimated preclinical AD duration was 10 years, prodromal AD 4 years, and dementia 6 years. Male sex, clinical setting, APOE epsilon 4 allele carriership, and abnormal cerebrospinal fluid tau were associated with a shorter duration, and these effects depended on disease stage. Discussion: Estimates of AD disease duration become more accurate if age, sex, setting, APOE, and cerebrospinal fluid tau are taken into account. This will be relevant for clinical practice and trial design. (C) 2019 the Alzheimer's Association. Published by Elsevier Inc. All rights reserved.
|
|
| 6. |
- Vieira-Silva, S., et al.
(författare)
-
Statin therapy is associated with lower prevalence of gut microbiota dysbiosis
- 2020
-
Ingår i: Nature. - : Springer Science and Business Media LLC. - 0028-0836 .- 1476-4687. ; 581:7808, s. 310-315
-
Tidskriftsartikel (refereegranskat)abstract
- Microbiome community typing analyses have recently identified the Bacteroides2 (Bact2) enterotype, an intestinal microbiota configuration that is associated with systemic inflammation and has a high prevalence in loose stools in humans1,2. Bact2 is characterized by a high proportion of Bacteroides, a low proportion of Faecalibacterium and low microbial cell densities1,2, and its prevalence varies from 13% in a general population cohort to as high as 78% in patients with inflammatory bowel disease2. Reported changes in stool consistency3 and inflammation status4 during the progression towards obesity and metabolic comorbidities led us to propose that these developments might similarly correlate with an increased prevalence of the potentially dysbiotic Bact2 enterotype. Here, by exploring obesity-associated microbiota alterations in the quantitative faecal metagenomes of the cross-sectional MetaCardis Body Mass Index Spectrum cohort (n=888), we identify statin therapy as a key covariate of microbiome diversification. By focusing on a subcohort of participants that are not medicated with statins, we find that the prevalence of Bact2 correlates with body mass index, increasing from 3.90% in lean or overweight participants to 17.73% in obese participants. Systemic inflammation levels in Bact2-enterotyped individuals are higher than predicted on the basis of their obesity status, indicative of Bact2 as a dysbiotic microbiome constellation. We also observe that obesity-associated microbiota dysbiosis is negatively associated with statin treatment, resulting in a lower Bact2 prevalence of 5.88% in statin-medicated obese participants. This finding is validated in both the accompanying MetaCardis cardiovascular disease dataset (n = 282) and the independent Flemish Gut Flora Project population cohort (n=2,345). The potential benefits of statins in this context will require further evaluation in a prospective clinical trial to ascertain whether the effect is reproducible in a randomized population and before considering their application as microbiota-modulating therapeutics. © 2020, The Author(s), under exclusive licence to Springer Nature Limited.
|
|
